Dosing completed
All volunteers have now received three doses of 2AP01 (AAVLP-HPV), our very broad spectrum HPV vaccine formulated without adjuvant. The vaccine is well tolerated and no serious adverse events (SAEs)have been observed to date.
...
2A Pharma
2A Pharma is a clinical stage Swedish/Danish biopharmaceutical company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented AAVLP platform.
Our Mission
To develop novel, cost effective prophylactic and therapeutic vaccines based on the AAVLP platform for the benefit of both future vaccine recipients and our investors.
LEARN MORE
Recent news
2A Pharma is a clinical stage Swedish/Danish biopharmaceutical company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented AAVLP Platform.
Article in MedWatch
Article about 2A Pharma in the Danish pharma/biotech media MedWatch (behind paywall):
Danish: https://medwatch.dk/secure/Medicinal___Biotek/article11272123.ece
English: https://medwatch.dk/secure/Top_picks_in_english/article11274345.ece
2A PHARMA INITIATES PHASE 1 CLINICAL TRIAL OF HPV VACCINE CANDIDATE
Malmö, Sweden – 13 March 2019
2A Pharma, the Swedish/Danish vaccine company today announced that, approximately 27 months after the company was founded, its novel, broad coverage, HPV L2 vaccine candidate formulated without...
